Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

The Lancet

Volumn 372, Issue 9633, 2008, Pages 117-126

  Eggermont, Alexander MM ^a   Suciu, Stefan ^b   Santinami, Mario ^c   Testori, Alessandro ^d   Kruit, Wim HJ ^a   Marsden, Jeremy ^e   Punt, Cornelis JA ^f   Salès, François ^g   Gore, Martin ^h   MacKie, Rona ⁱ   Kusic, Zvonko ^j   Dummer, Reinhard ^k   Hauschild, Axel ^l   Musat, Elena ^b   Spatz, Alain ^m   Keilholz, Ulrich ⁿ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JULES BORDET INSTITUTE   (Belgium)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT;

EID: 46749103710     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61033-8     Document Type: Article

References (26)

1. Balch C., Soong S.-J., Gershenwald J., et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19 (2001) 3622-3634
2. Eggermont A., and Gore M. European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. Semin Oncol 29 (2002) 382-388
3. Wheatley K., Ives N., Hancock B., Gore M., Eggermont A., and Suciu S. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29 (2003) 241-252
4. Kirkwood J., Strawderman M., Ernstoff M., Smith T., Borden E., and Blum R. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
5. Kirkwood J., Ibrahim J., Sondak V., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 18 (2000) 2444-2458
6. Kirkwood J., Manola J., Ibrahim J., Sondak V., and Ernstoff R.U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10 (2004) 1670-1677
7. Eggermont A., Suciu S., MacKie R., et al., for the EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005) 1189-1196
8. Grob J., Dreno B., de la Salmonière P., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases. Lancet 351 (1998) 1905-1910
9. Pehamberger H., Soyer P., Steiner A., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16 (1998) 1425-1429
10. Cascinelli N., Belli F., MacKie R., Santinami M., Bufalino R., and Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358 (2001) 866-869
11. Hancock B., Wheatley K., Harris S., et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22 (2004) 53-61
12. Wheatley K., Ives N., Eggermont A., et al., on behalf of International Malignant Melanoma Collaborative Group. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 25 suppl (2007) 8526
13. Glue P., Fang J., Rouzier-Panis R., et al. Pegylated interferon-α2b: pharmacokinetics, pharmaco-dynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68 (2000) 556-557
14. Bukowski R., Tendler C., Cutler D., Rose E., Laughlin M., and Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 15 (2002) 389-396
15. Michallet M., Maloisel F., Delain M., et al., for the PEG-Intron CML Study Group. Pegylated recombinant interferon-alpha-2b vs recombinant interferon-alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 18 (2004) 309-315
16. Hwu W., Panageas K., Menell J., et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 106 (2006) 2445-2451
17. Spieth K., Kaufmann R., Dummer R., et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol 19 (2008) 801-806
18. Pocock S., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975) 103-115
19. Freedman L., and White S. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32 (1976) 691-694
20. Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. National Cancer Institute. Revised March 23, 1998; published April 30, 1999. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf (accessed March 7, 2007).
21. Kalbfleisch J., and Prentice R. The survival analysis of failure time data. 2nd edn. (2002), Wiley Inter-Science, Hoboken, NJ
22. Peduzzi P., Wittes J., Detre K., and Holford T. Analysis as-randomized and the problem of non-adherence: an example from the veterans affairs randomized trial of coronary artery bypass surgery. Stat Med 12 (1993) 1185-1195
23. Balch C., and Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med 355 (2006) 1370-1371
24. Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709-718
25. Bouwhuis M., Suciu S., Testori A., et al. Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon alpha-2b vs observation. Eur J Cancer 6 suppl 5 (2007) 5
26. Bouwhuis M., Suciu S., Kruit W., et al. Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) vs observation (Obs). J Clin Oncol 25 suppl (2007) 8507